DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell Disease
The most common cause of hospital admission among patients with sickle cell disease (SCD) are excruciating pain crises, for which opioid medications are a mainstay of treatment. There have been questions about whether the US opioid epidemic, which has resulted in large increases in opioid-related overdoses and deaths over the past 2 decades, may have affected the death rate among patients with SCD who were treated with opioids in the hospital to relieve pain crises.
According to a study results presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, California, on December 2, 2018, the use of opioid medications for pain control in SCD is relatively safe, and there has been no associated increase in hospital SCD mortality.
Related Content
-
news & eventsHow sickled red blood cells stick to blood vesselsOne of the most common complications o...
-
education & researchSickle cell disease in the emergency departmentAcute painful episodes are the most comm...
-
education & researchMechanisms of Pain in Sickle Cell DiseaseObjectives: The hallmark of sickle cell...
-
news & eventsA multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
-
news & eventsGBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
-
news & eventsSCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
news & eventsLong-term opioids may not be best pain management option for all sickle cell patientsSmall study shows some on opioids report...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.